

# COVID-19 VACCINATION SUPPORT SERVICES



**Dr Neil Nerwich**  
Group Medical  
Director,  
Assistance



**Dr Anthony Renshaw**  
Regional Medical  
Director, Health  
Consulting



**Cédric Fraissinet**  
General Manager  
Switzerland & Italy



This webinar is recorded,  
and you remain in  
view-and-listen-only mode



Follow-up emails  
containing links to survey  
and recording

# COVID-19 VACCINATION SUPPORT SERVICES

## Agenda



Dr Neil Nerwich

**Subscription services in support of your COVID-19 & vaccine related challenges**



Dr Anthony Renshaw

**Tailored planning & implementation of vaccination strategy**







# COVID-19 VACCINATION SUPPORT SERVICES

## Provide intelligence & advise your staff and management






# ASSESS VACCINATION SITUATION





# COVID-19 vaccines in use: detailed information





David Heimerlin... ▾

CONTACT US

Monitor / Active Threat: COVID-19

Location Insights

Intelligence & Forecasting

Related Materials

Scientific Update


Security Analysis & Forecasting

The Scientific Update is a weekly compendium of items relating mainly to immunity and vaccine development.

INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 26 MARCH 2021	Download document	26 Mar 2021 07:28 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 MARCH 2021	Download document	19 Mar 2021 06:40 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 12 MARCH 2021	Download document	12 Mar 2021 11:28 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 5 MARCH 2021	Download document	05 Mar 2021 11:00 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 2 MARCH 2021	Download document	05 Mar 2021 10:57 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 26 FEBRUARY 2021	Download document	26 Feb 2021 09:08 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 FEBRUARY 2021_SG	Download document	19 Feb 2021 11:10 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 FEBRUARY 2021	Download document	19 Feb 2021 11:02 GMT



ASSESS RISKS



# Vaccine-related scientific updates



2019-nCoV

COVID-19 Vaccine

COVID-19 VACCINE

SCIENTIFIC UPDATE

COVID-19 OVERVIEW

COVID-19 DATA VISUALISATION

COVID-19 MODELLING

USE OF FACE MASKS BY THE GENERAL PUBLIC

COVID-19 TESTING

COVID-19 TREATMENT

COVID-19 VACCINE

COVID-19 VACCINE FAQs

TRAVEL RESTRICTIONS FLIGHT OPERATIONS AND SCREENING

LOCATIONS WITH CASES

COVID-19 CASE COUNT TRACKER

COVID-19 VACCINATION MYTHS VS FACTS

Vaccination against COVID-19 has begun in many countries. For detail on the situation in each country, see the relevant **country page on this website** (access restricted to Pandemic Information Service / Site Monitor subscribers\*), and the **VACCINE DISTRIBUTION CHARTS** below. The **COVAX programme** aims to provide vaccine to at least 20% of the population of lower-income countries. \*please contact your account manager if you do not have subscription and are interested in access

There are hundreds of vaccines continuing through clinical trials and approval processes (see **VACCINE TRACKERS** section below for links to websites that track development and approvals, **WHO Draft landscape and tracker of COVID-19 candidate vaccines**)

Vaccines in Use

Bharat Biotech Covaxin

CanSino Biologics (Convidicea)

Gamaleya Sputnik V

Moderna

Oxford/ AstraZeneca (Covishield)

Pfizer/BioNTech Comirnaty

Sinopharm

Sinovac CoronaVac

COVID-19 Vaccine FAQs

COVID-19 Vaccination Benefits Infographic

COVID-19 VACCINATION

Protect Yourself & The Community

While vaccination is ongoing, all who are immediately eligible are encouraged to be vaccinated.

If you have any questions or need more information, please contact your local health authority or visit our website for more information.

ALL COVID-19 VACCINE NEWS

1 2 3 4 5 ...

VACCINE UPDATE - VACCINATION BEGINS IN AUCKLAND

New Zealand // 20 February, 2021

Border and managed isolation and quarantine workers in Auckland being vaccinated....

COVID-19

EU TO DOUBLE FUNDING TO COVAX

Germany // 19 February, 2021

Additional €500 million pledged...

COVID-19

PFIZER-BIONTECH VACCINE STABLE AT HIGHER TEMPERATURES

19 February, 2021

New data submitted to regulatory agency...

COVID-19, General Articles

JOHNSON AND JOHNSON APPLY TO WHO FOR EUA

19 February, 2021

Up to 500 million doses could be provided to COVAX...

COVID-19, General Articles

VACCINE UPDATE - CAMPAIGN ROLLING OUT IN MORE PREFECTURES, SECOND SHIPMENT DUE

Japan // 19 February, 2021

The vaccination campaign is underway, with healthcare workers in a dozen prefecture being vaccinated...

COVID-19

2019-nCoV

Scientific Update

SCIENTIFIC UPDATE

SCIENTIFIC UPDATE

COVID-19 OVERVIEW

COVID-19 DATA VISUALISATION

COVID-19 MODELLING

USE OF FACE MASKS BY THE GENERAL PUBLIC

COVID-19 TESTING

COVID-19 TREATMENT

COVID-19 VACCINE

COVID-19 VACCINE FAQs

TRAVEL RESTRICTIONS FLIGHT OPERATIONS AND SCREENING

LOCATIONS WITH CASES

COVID-19 CASE COUNT TRACKERS

COVID-19 VARIANTS

FAQS

EDUCATION AND COMMUNICATION

COVID-19 VIDEOS

MEMBERS Q&AS

INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE

**Focussing on immunity and vaccine development**

**Produced by Dr Doug Quarry**

**19 February 2021**

**In this week's summary:**

**19 February:**

**PART 1: Mutations and Variants**

1.1 Coronavirus mutations

1.2 The most significant mutations

1.3 Summary of the major variants

1.4 Where B.1.1.7 variant, first identified in the UK, has been found

1.5 Where B.1.351 variant, first identified in the South Africa, has been found

1.6 Where P.1 variant, first identified in Brazil, has been found

**PART 2: Variant News**

2.1 South Africa suspends use of AstraZeneca's COVID-19 vaccine

2.2 South Africa to start COVID-19 vaccinations with J&J doses

2.3 Israel: 94% drop in symptomatic COVID cases after two Pfizer shots

2.4 Three Israelis who have recovered from COVID have been reinfected with B.1.351 variant

2.5 In vitro immune evasion of the B.1.351 variant (South Africa) to both the mRNA vaccines

2.7 Possible new reason for B.1.1.7 increased infectiousness

2.7 Keeping up-to-date with variants

**16 February:**

1. Study suggests AstraZeneca vaccine does not protect against mild/moderate COVID-19

2. Update on the three major variants by Eric Topol

3. Rise in pediatric proportion of Israeli COVID-19 cases over 2020

4. Reinfection warning from the WHO

5. Singapore Airlines becomes second airline to have fully vaccinated crew

6. WHO gives emergency vaccine approval to AstraZeneca/Oxford vaccine

7. AstraZeneca/Oxford vaccine to begin trials in children

8. France recommends single vaccine dose for people who have already had COVID-19

9. Australian churches on collision course with the government over AstraZeneca vaccine

10. Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine


11. Pakistan lab expects Sputnik V doses for commercial sale in a week

12. Two Swedish regions pause AstraZeneca vaccinations after mild side-effects

13. The five key mitigation strategies from the CDC's new guidance to reopen schools



ASSESS RISKS



# Key global vaccine trackers



## VACCINE TRACKERS

McGill University  
New York Times  
London School of Hygiene and Tropical Medicine  
WHO Draft landscape of COVID-19 vaccine candidates  
Regulatory Affairs Professional Society  
Milken Institute  
Artis Ventures  
Bloomberg COVID-19 Vaccine Tracker  
UNICEF - Vaccine Market Dashboard  
CDC Vaccine Tracker - US Only  
Statistics and Data COVID-19 Vaccinations Data  
ECDC Vaccine Tracker



## COVID-19 - Landscape of novel coronavirus candidate vaccine development worldwide

19 February 2021

DISCLAIMER: These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 pandemic of the novel coronavirus, including any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity for any of its purposes or activities. While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (direct or indirect) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose, timeliness, reliability, quality, safety, efficacy, technological and/or non-regulatory information provided in these landscape documents and/or of any of the products referenced therein. WHO also declines any and all liability or responsibility for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

### Summary information on Vaccine Products in Clinical Development

1. - Number of vaccines in clinical development: 70

2. - Number of vaccines in pre-clinical development: 181


### 3. - Candidates in clinical phase



ASSESS RISKS

## COVID-19 vaccine doses administered per 100 people, Feb 20, 2021


Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).



Our World in Data

## Daily COVID-19 vaccine doses administered per 100 people, Feb 20, 2021

Shown is the rolling 7-day average per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).




Our World in Data

## Vaccine Trial & Approval Map



## COVID-19 vaccine doses administered per 100 people, Feb 20, 2021

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).





# Related latest trusted news

## ALL COVID-19 VACCINE NEWS

1 2 3 4 5 ... >

### > VACCINE UPDATE - VACCINATION BEGINS IN AUCKLAND

New Zealand // 20 February, 2021  
Border and managed isolation and quarantine workers in Auckland being vaccinated....

COVID-19

### > EU TO DOUBLE FUNDING TO COVAX

Germany // 19 February, 2021  
Additional €500 million pledged...

COVID-19

### > PFIZER-BIONTECH VACCINE STABLE AT HIGHER TEMPERATURES

19 February, 2021  
New data submitted to regulatory agency...

COVID-19, General Articles

### > JOHNSON AND JOHNSON APPLY TO WHO FOR EUA

19 February, 2021  
Up to 500 million doses could be provided to COVAX...

COVID-19, General Articles

### > VACCINE UPDATE - CAMPAIGN ROLLING OUT IN MORE PREFECTURES, SECOND SHIPMENT DUE

Japan // 19 February, 2021  
The vaccination campaign is underway, with healthcare workers in a dozen prefecture being vaccinated...



ASSESS RISKS

Report

## EU TO DOUBLE FUNDING TO COVAX

GERMANY // 19 FEBRUARY, 2021

The European Union (EU) announced today they will put forward another €500 million to the COVAX Facility. The additional funds double their contribution so far, bringing it to €1 billion. Germany has also pledged a further €900 million today. Team Europe is leading the way with contributions to the COVAX Facility, with more than €2.2 billion.

## LATEST NEWS

1 2 3 4 5 ... >

### > FIRST EVER HUMAN CASES OF H5N8 BIRD FLU

Russia // 21 February, 2021  
Seven poultry workers are the first known human cases...  
Bird flu other strains; Influenza H5N8

### > EBOLA OUTBREAK GROWING IN N'ZEREKORE, ONE CASE IN CONAKRY

Guinea // 20 February, 2021  
Suspected and confirmed Ebola cases in Guinea  
Ebola

### > VACCINE UPDATE - VACCINATION BEGINS IN AUCKLAND

New Zealand // 20 February, 2021  
Border and managed isolation and quarantine workers in Auckland being vaccinated....  
COVID-19

### > SUSPECTED EBOLA CASE UNDER INVESTIGATION

Liberia // 19 February, 2021  
Case linked to outbreak in Guinea...  
Ebola

### > ECDC RECOMMENDATIONS TO CONTROL SPREAD OF COVID-19 IN MINKS




**Pandemic Information Webinars**  
(Available to Pandemic Subscribers only)  
Register for upcoming events  
View/Download previous webinars





**MERS-CoV Information**  
MERS-CoV FAQs





# FEED YOUR COVID RESPONSE PLANS WITH UPDATED INFORMATION





# Online COVID-19 response plans repository



< Back to Previous

## Monitoring

Activate Plan

Corp/All Assets

Location (255) ▾

Last searches

Topic (163) ▾

Last searches

Language (1) ▾

Last searches

## Planning

*\*Please contact your International SOS account manager for more information.*

### Infectious (28)

Avian Influenza (H5N1) Avian Influenza (H7N9)  
Bird Flu (Avian Influenza) COVID-19  
COVID-19 Return to Ops COVID-19 Return to Tr...  
Chickenpox (Varicella) Chickenpox Offshore  
Cholera Ebola  
Ebola Travel Managem... Hand Foot and Mouth ...  
Hepatitis MERS-CoV

### Vector-borne (5)

Chikungunya Dengue Fever  
Malaria Yellow Fever  
Zika Virus

### Environment (10)

Air Pollution Cyclone  
Earthquake Flood  
Heat Illness Hurricane  
Legionnaires' Disease Snowstorm / Extreme ...  
Typhoon Wildfire

### Operations (7)

General Information Active Shooter  
Bomb Threat Civil Unrest  
Explosion Work Related Case  
\_Travel Risk Managem...

Scroll down to view more

Search Results: 2567 Resources

Add

Edit

Unhide

Hide

Refine search with keyword or resource type.

Enter Keyword



Show more search options ▾



PLAN

COVID-19 Pandemic News & Info



Intl SOS

91-DIVOC: An interactive visualization of the ex...



Intl SOS

Active Screening Alert Poster




Intl SOS

91-DIVOC: An interactive visualization of the ex...




Active Shooter Overview

# SOCIALISE VACCINES AMONG YOUR EMPLOYEES







# Vaccination frequently asked questions



SCIENTIFIC UPDATE

COVID-19 OVERVIEW

COVID-19 DATA VISUALISATION

COVID-19 MODELLING

USE OF FACE MASKS BY THE GENERAL PUBLIC

COVID-19 TESTING

COVID-19 TREATMENT

COVID-19 VACCINE

COVID-19 VACCINE FAQs

TRAVEL RESTRICTIONS FLIGHT OPERATIONS AND SCREENING

LOCATIONS WITH CASES

COVID-19 CASE COUNT TRACKERS

COVID-19 VARIANTS


FAQS


EDUCATION AND COMMUNICATION

COVID-19 VIDEOS

MEMBERS Q&AS

TRAVEL ADVICE

 > 2019-nCoV > COVID-19 Vaccine FAQs

COVID-19 VACCINE FAQs

COVID-19 vaccines have been developed at an unprecedented rate. Over 50 vaccines are in human trials. Some vaccines have received authorisation for use in a small number of countries. Several countries have commenced vaccination of priority groups, and many more are expected to commence in coming months. Almost all countries are in the process of procuring, approving and planning their distribution and administration of vaccine. Meanwhile many vaccine candidates continue to be developed and tested. The situation is dynamic. International SOS is monitoring the situation closely. The latest updates are in the News section of this website and the individual country pages.

### Frequently Asked Questions

#### Is there a vaccine available against COVID-19?

Yes but currently only in a few countries and there is a number of different COVID-19 vaccines now being used. Due to relatively limited supplies, they are in general reserved for high priority groups (such as healthcare workers and elderly people living in aged care facilities). It is expected that as more vaccines are approved, and supply improves, vaccine will be available to more people in more locations. For more information see the [Vaccine](#) page of this website.

#### Do you have a list of countries where vaccination is available?

International SOS is monitoring the information and publishing it on this website for members. Select the country of interest on the Locations page, and scroll down to the "news" section. We hope to be able to publish this in a consolidated table format. If you require more information, contact any International SOS assistance centre or our [Health Consulting](#) teams.

#### Can we purchase vaccine and import it for our employees?

Currently private organisations cannot access vaccine outside of the local national / state processes. Globally, vaccines are considered medical therapeutics, and are governed by national regulations for importation and use. Each jurisdiction has its own requirements. COVID-19 vaccines are expected to be progressively approved, produced and made available under the control of national health authorities in 2020/2021. Authorities are likely to initially control the access and the distribution of the vaccines while supplies are limited.

#### Can I have one brand for the first shot, and a different brand for the second?

Ideally both doses should be of the same vaccine. Many health authorities, including CDC have said the two vaccines are not interchangeable. However CDC guidance now adds, "In exceptional situations in which the first-dose vaccine product cannot be determined or is no longer available, any available mRNA COVID-19 vaccine may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 vaccination series. If two doses of different mRNA COVID-19 vaccine products are administered in these situations (or inadvertently), no additional doses of either product are recommended at this time." Every effort should be made, however, to use the same product both times as interchangeability has not been evaluated. In the UK, officials state that in the rare event that the same kind isn't available or if it's not known what was given for the first shot, it's OK to give whichever vaccine is available for the second shot. Since the Pfizer and AstraZeneca vaccines work in a similar way, they say a mismatched dose is better than partial protection.

# COVID-19 educational material

## COVID-19 VACCINATION

### Protect Yourself & The Community

**COVID-19 VACCINES ARE SAFE AND EFFECTIVE**  
All COVID-19 vaccines have to undergo rigorous testing as follows:

**3 phases of clinical trials**  
Approval process of Stringent Regulatory Authorities

**COVID-19 VACCINATION SAVES LIVES**  
Vaccination **reduces** the risks of infection, especially severe infection that leads to hospitalisation.  
This will help keep our hospitals and healthcare facilities from being overwhelmed.

Vaccinated people are **probably less likely to transmit** COVID-19.

Enough vaccinated people can **reduce the spread**.

The **community will be safer**, especially for those who cannot be vaccinated.

Vaccination can contribute to a **safe & gradual reopening of the economy & society**.

**While vaccination is voluntary, all who are medically eligible are encouraged to be vaccinated.**

Millions of people have been vaccinated. Reports of serious side effects have been very rare and no long term complications reported.

Seek facts, backed by research and data, published by credible health care providers and organisations. Avoid spreading misinformation.

WHO ECDC CDC

**Be aware of scams** pretending to provide COVID-19 vaccines. Only participate in vaccination programmes authorised by your local health authorities.

**If you have any questions or doubts about COVID-19 vaccination, reach out to your trusted doctors and health providers for clarification.**

© International SOS 2021. All rights reserved.

## COVID-19 VACCINATION

### MYTHS VS FACTS



## COVID-19 VACCINATION

### MYTHS VS FACTS

**MYTH**  
I have already had COVID-19 so I don't need to be vaccinated.

**FACT**  
Most authorities advise even people who have had COVID-19 infection to be vaccinated, although you may be advised to wait for at least 90 days after your infection. **Speak to your doctor for an individual recommendation.**

We do not yet know how long the protection from your immunity developed by a COVID-19 infection will last.

© International SOS 2021. All rights reserved.

## COVID-19 VACCINATION

### MYTHS VS FACTS

**MYTH**  
The fatality rate of COVID-19 is so low so I do not need to be vaccinated.

**FACT**  
COVID-19 vaccines protect yourself, your family, colleagues and your community. They reduce the risk of severe infection and hospitalisation. People who are vaccinated are **probably less likely to transmit** the disease. When the majority of the population are vaccinated it will protect the community, including the vulnerable and those who cannot be vaccinated.

While vaccination is voluntary, all who are medically eligible are encouraged to be vaccinated.

© International SOS 2021. All rights reserved.

## INTERNATIONAL SOS

David Heimerlin...

Monitor / Active Threat: COVID-19

Location Insights Intelligence & Forecasting Related Materials

Video Resources Workflow Education

### Educational Materials from International SOS

<b>TRANSMISSION INFOGRAPHIC</b>  Click <a href="#">HERE</a> to download an infographic highlighting factors to reduce the risk of COVID-19 transmission.	<b>COVID-19 VACCINE BENEFITS</b>  Click <a href="#">HERE</a> to download an infographic outlining the key benefits of the COVID-19 vaccination.	<b>COVID-19 VACCINE MYTHS &amp; FACTS</b>  Click <a href="#">HERE</a> to download a document showing myths versus facts about the COVID-19 vaccine.
<b>HOTEL QUARANTINE INFOGRAPHIC</b>  Click <a href="#">HERE</a> to download COVID-19 hotel quarantine infographic about coping with the situation.	<b>USE OF FACE MASKS</b>  Click <a href="#">HERE</a> to download guidelines about the use of face masks by the general public.	<b>WHAT YOU NEED TO KNOW SLIDES</b>  Click <a href="#">HERE</a> to download PowerPoint slides explaining what you need to know about COVID-19.




EDUCATE



# Tailored COVID-19 vaccination educational webinars

**Vaccine Myth Buster**  
Introduction

The graphic features a background image of a healthcare worker in a white coat and blue surgical mask administering a vaccine to a patient's arm. Overlaid on this is a dark blue banner with the text 'Welcome to this micro learning on: Vaccines'. Below the banner are two circular icons: one showing a pink virus particle and a blue syringe, and the other showing a blue smartphone with a pink megaphone icon. At the bottom, a pink banner contains the text: 'This short module is designed to help you understand the critical role that vaccines play in reducing the spread of COVID-19.' The International SOS logo is in the top right corner.



EDUCATE

**INTERNATIONAL SOS**


David Heimerlin... ▾

Monitor / Active Threat: COVID-19


Location Insights

Video Resources


Video Materials from International SOS

A video thumbnail with a black background and blue and white text. It includes a play button icon, a progress bar, and a timestamp of 13:38. To the right of the video are icons for heart, clock, and share.

08 Mar 2021  
COVID-19 Va  
This is a Web


A video thumbnail with a dark blue background and white text. It includes a play button icon, a progress bar, and a timestamp of 13:38. To the right of the video are icons for heart, clock, and share.

04 Nov 2020  
Year Review  
A reflection o

A video thumbnail with a blue background and white text. It includes a play button icon, a progress bar, and a timestamp of 13:38. To the right of the video are icons for heart, clock, and share.

18 Sep 2020





# STAY UPDATED 24/7 WITH ANY NEW COVID-19 RELATED ISSUE



# Real time COVID-19 alerts to managers

The screenshot displays the International SOS Monitor interface. The top navigation bar includes the International SOS logo, a user profile for David Heimerlin, and a 'CONTACT US' button. The left sidebar contains navigation links: Monitor, Active Threat: COVID-19, Alerts, Locations, Reporting, My Company, and Resources. The main content area is titled 'Monitor' and shows a list of 'Alerts (196)'. The alerts are filtered by 'Security' and 'Advisory' categories. The first alert is for Mauritius, dated 26 Mar 2021 15:23 GMT, with a 'COVID (Travel): Very High' severity. The second alert is for Pakistan, dated 26 Mar 2021 14:45 GMT, with a 'COVID (Domestic Ops): Medium' severity. The third alert is for the Philippines, dated 26 Mar 2021 14:12 GMT, with a 'COVID (Travel): Very High' severity. Each alert includes a 'Read full alert >' link.

INTERNATIONAL SOS

David Heimerlin...

CONTACT US

Monitor

Alerts (196)

Filter options Reset

Date 1 to 10 of 196 records

Security Advisory COVID (Travel): Very High COVID (Domestic Ops): Medium

26 Mar 2021 15:23 GMT - Last updated 5 minutes ago

Mauritius | COVID-19: Continue to defer all travel amid suspension of international flights until 15 April, nationwide lockdown extension until 31 March [more detail +](#)

[Read full alert >](#)

Security Notice

26 Mar 2021 14:45 GMT - Last updated 43 minutes ago

Pakistan | Quetta: Avoid protest outside Press Club on 27 March (Correction) [more detail +](#)

[Read full alert >](#)

Security Notice


26 Mar 2021 14:12 GMT - Last updated 1 hour ago

Philippines | Expect significant disruption, heightened security during Holy Week from 28 March-4 April [more detail +](#)

[Read full alert >](#)



MONITOR



# Medical updates for managers



Monitor

Active Threat: COVID-19

Alerts

Locations

Neil Nerwich ▾

CONTACT US

Monitor / Active Threat: COVID-19

Location Insights

Intelligence & Forecasting

Related Materials

Scientific Update

Security Analysis & Forecasting

The Scientific Update is a weekly compendium of items relating mainly to immunity and vaccine development.

INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 5 MARCH 2021	<a href="#">Download document</a>	05 Mar 2021 11:00 GMT
INTERNATIONAL SOS INSTANT SCIENTIFIC UPDATE 2 MARCH 2021	<a href="#">Download document</a>	05 Mar 2021 10:57 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 26 FEBRUARY 2021	<a href="#">Download document</a>	26 Feb 2021 09:20 GMT
INTERNATIONAL SOS WEEKLY SCIENTIFIC UPDATE 19 FEBRUARY 2021_SG	<a href="#">Download document</a>	19 Feb 2021 11:10 GMT



# Medical updates for managers



INTERNATIONAL SOS

David Heimerlin... ▾

CONTACT US

Monitor / Active Threat: COVID-19

Location Insights

Intelligence & Forecasting

Related Materials

COVID Impact

News & Status

Interactive Data

News & Status

Q Enter a location for specific insights X

COVID-19 News for All Locations

COVID-19 Status for All Locations

26 Mar 2021 - [Bulgaria: Vaccine update - vaccination open to everyone](#)

26 Mar 2021 - [Palestinian Territory: Vaccine Update: Nationwide campaign underway...](#)

26 Mar 2021 - [Nepal: COVID-19 update: Quarantine measures changed for fully vaccinated visitors](#)

26 Mar 2021 - [Australia: Vaccine update - Locally manufactured AstraZeneca supplies rolled out](#)

26 Mar 2021 - [Australia: Community-acquired case in Brisbane](#)


26 Mar 2021 - [Philippines: Healthcare overwhelmed due to COVID-19](#)

26 Mar 2021 - [Study: SARS-CoV-2 can infect the mouth and salivary glands](#)

123...next

123...next

MONITOR



# Medical updates for managers



pandemic.internationalsos.com/countries/austria

## Pandemic PREPAREDNESS

### ACTIVE THREATS

- COVID-19 ✓
- Bird flu other strains ✓
- Ebola ✓
- MERS-CoV ✓
- Seasonal Flu ✓
- Influenza G4 EA H1N1 ✓

WATCHING +

**MONITOR**

> Austria

## AUSTRIA

Updated: February 2021

### Coronavirus Disease 2019 (COVID-19)

The first cases of COVID-19 were reported in late February 2020, and local transmission was later detected. See the *Latest News* items below.

For general information regarding COVID-19, **helpline is 0800 555 621** which is open 24 hours. If you suspect you are infected, **call 1450**.

**Cases:** As of 16 February, there are 432,469 confirmed cases and 8,164 deaths since the start of the pandemic. Active cases currently stand at 20,935.

**Status:** **Outbreak**

**Vaccine:** The Pfizer/BioNTech COVID-19 vaccine COMIRNATY received [conditional approval \(in German\)](#) from the European Commission in December. Vaccination began on 27 December at the Medical University of Vienna. The highest priority are elderly people and health workers in long-term care facilities.


**Websites:** View the Government [website \(in German\)](#) for updates on COVID-19 in the country. The national vaccination strategy is [here \(in German\)](#). The country's vaccination dashboard can be found [here \(in German\)](#).

Search

© Mapbox © OpenStreetMap Improve this map

**Pandemic Information Webinars**

**MERS-CoV Information**  
MERS-CoV FAQs



# Medical updates for managers



pandemic.internationalsos.com/reports/batch-of-astrazeneca-vaccine-suspended-after-recipient-died-mar-07-2021



Home Overview COVID-19 Subscribers Locations Newsroom

About Us Careers CSR Foundation

Member

English

Search

## Pandemic PREPAREDNESS

### ACTIVE THREATS



COVID-19



MONITOR




Report


## BATCH OF ASTRAZENECA VACCINE SUSPENDED AFTER RECIPIENT DIED

AUSTRIA // 07 MARCH, 2021

Austria's Federal Office for Safety in Health Care (BASG) received reports of one death and one other serious adverse event among people who had received the AstraZeneca COVID-19 vaccine from the same batch. Both patients were vaccinated in the district clinic of Zwettl, in Lower Austria province. A 49-year-old woman died from a blood clotting disorder, and a 35-year-old woman developed a pulmonary embolism (a blood clot in the lungs.) The BASG said, "Currently there is no evidence of a causal relationship with the vaccination.[...] According to current knowledge, the clinical data do not show any worrying data or signals in this respect compared to placebo. [...] At present, all necessary investigations involving the respective experts are running at full speed in order to be able to completely exclude a possible connection. To be on the safe side, the remaining stocks of the affected vaccine batch will no longer be distributed and vaccinated."







pandemic.internationalsos.com/reports/vaccine-update---10-million-more-doses-of-pfizer-vaccine-secured-feb-04-2021

Home Overview COVID-19 Subscribers Locations Newsroom

English

Pandemic  
**PREPAREDNESS**

ACTIVE THREATS

COVID-19

Report


## VACCINE UPDATE - SOME ASTRAZENECA SUPPLIES RECEIVED, ONSHORE SUPPLIES EXPECTED LATER THIS MONTH

AUSTRALIA // 09 MARCH, 2021


**9 March:** Phase 1A of the vaccination campaign continues - so far over 86,000 people have received a dose of vaccine. Some supplies of the AstraZeneca vaccine have been received, and the first vaccinations with this brand started in South Australia. However supplies from overseas have been delayed as the European Commission has refused to authorise export of the vaccine. The first doses of locally-produced AstraZeneca vaccine (manufactured onshore by CSL) will be available by the 22 March - the plan is to produce a total of 50 million doses.

In February, a doctor who was vaccinating residents of an aged-care facility in Brisbane inadvertently administered an excessive amount of vaccine.


**23 February:** Vaccination campaigns kicked off in Australia on 22 February in **Australian Capital Territory, New South Wales, Northern Territory, Queensland, South Australia, Victoria** and **Western Australia**. On the first day, there were around 1,300 doses administered in **New South Wales**, 580 in **Victoria** and over 200 in **Queensland**.



© Mapbox © OpenStreetMap Improve this map



Pandemic Information



MERS-CoV Information

MONITOR

# COVID-19 impact scaling & travel restrictions




International inbound/outbound, domestic travel advice and COVID-19 impact scale tool

The screenshot shows the International SOS COVID-19 Impact Advisor tool. The interface has a dark blue sidebar on the left with icons for Monitor, Active Threat: COVID-19, Alerts, Locations, Reporting, My Company, and Resources. The top header includes the International SOS logo, a user profile for "David Heimerlin...", and a "CONTACT US" button. The main content area is titled "Monitor / Active Threat: COVID-19" and has three tabs: "Location Insights" (selected), "Intelligence &amp; Forecasting", and "Related Materials". Under "Location Insights", there are three sub-tabs: "COVID Impact" (selected), "News &amp; Status", and "Interactive Data". The "COVID Impact Advisor" section features a search bar with filters for "United States - All States", "United Kingdom", "Japan", and "Australia". Below the search bar are options to "Show Last 24 Hours" and "Filter Options", along with a "Run Report" button. The results for "Australia" show a "COVID Impact Rating (Travel): High" and a "COVID Impact Rating (Domestic Operations): Low". A "View All Definitions" link is also present. Under the "Restrictions" section, it lists "Inbound" travel restrictions, stating that all non-resident travellers are banned from entering Australia, with a list of exemptions including Australian citizens, permanent residents, immediate family members, New Zealand citizens, and diplomats.



MONITOR




# COVID-19 pandemic information via email updates



Pandemic Update 17 February 2021



International SOS <pandemic\_updates@learn.international.sos>  
To: Neil NERWICH MD



Wed 17/02

**Must Attend**

If there are problems with how this message is displayed, click here to view it in a web browser.

## PANDEMIC INFORMATION



### Update - 17 February 2021

Dear Neil

#### In this edition:

- COVID-19
- Ebola
- MERS-CoV
- Avian influenza

#### Highlights

- B.1.1.7 from the UK may be more deadly - NERVTAG update
- CDC - fully vaccinated people do not need to quarantine after exposure
- Ebola outbreak declared in Guinea

#### COVID-9 vaccination has recently begun in the following countries:

- Cambodia
- Dominica
- Lebanon


#### COVID-19

Since the last Pandemic Update on 10 February, the number of new cases reported has slowed. Globally, there are 110 million cases and over 2.42 million deaths.





**MONITOR**








# ENSURE YOUR STAFF IS WELL INFORMED







# COVID-19 alerts & information via app



INFORM STAFF




# ENSURE YOUR LOCAL MANAGEMENT TAKES INFORMED DECISIONS





# On call COVID-19 vaccination support

- Information & advice provided by medical professionals to managers
- More complex issues can be escalated to our consultants


**International SOS**

**AC COVID Tracker**

**Germany**

Country: Germany  
State/Region: All

Data last refreshed: 18/02/2021 06:05 UTC

**Int'l SOS Pandemic Status**  
**Outbreak**

**Latest Data**  
**15/02/2021**

**Total Cases**  
**2,352,766**  
Prev Day: 2,346,876 (+0.25%)

**New Case 7DA**  
**7,245**  
Prev Day: 7,222 (-0.32%)

**Vaccine Program Start**  
**27/12/2020**

**Vaccines Available**  
**MD, OX/AZ, P/BN**

**Gov. Roll-out Policy**  
**2G**

**Case trend over last 28 days**  
**-32.98%**

**Total Vaccinations**  
**4,284,554**  
Prev Day: 4,162,766 (+2.93%)

**Days since last case**  
**0**

**Daily Vaccinations (7DA)**  
**123,616**  
Prev Day: 120,305 (+3.31%)

**% Vaccinated /day (7DA)**  
**0.15%**  
Prev Day: 0.14% (+0.00%)

**Medical Risk Rating**  
**Low**

**Travel Risk Rating**  
**Low**

**Travel Impact Scale**  
**High**

**Domestic Impact Scale**  
**Low**

Do non-nationals have access to vaccine?

Yes all people living in Germany have access to vaccine independently of

**Medical Country Guidance**

1. Guidance for symptomatic individuals, National Hotline(s) & Online Symptom Checkers  
Symptomatic patients should contact their local GP, the local health authority ("Gesundheitsamt") - see Link 4 for website details and insert the person's postcode). Alternatively, patients can call the national-wide number using cell phone only: 116117 (Kassenärztlicher Notdienst) for further support. This is not an emergency number but can help with medical orientation. The automated phone system will request the postcode, which will then need to be entered, to provide nearest provider in their location. Emergencies should call 112. See Link 7. Ministry of Health - Link 1 and Robert Koch Institute COVID-19 o

2. Impact on Healthcare system  
Nil information obtained at the moment, the health system is stressed but still working.

3. Designated COVID-19 Providers for Treatment  
Private HCD services can also provide medical advice (via consultation).

4. National Testing Capabilities  
Many districts have central test centers. Generally, private laboratories can do tests but the medical need shall be co available (no antigen testing) in approved laboratories only, samples taken from Drive-thru clinics, GP practice and h

Testing requires a referral from a clinician and to meet the testing criteria: fever, acute respiratory infection (e.g. short confirmed case, been recently abroad. Cost is 200 EUR. Turnaround time for results 24-48 hrs.

Private PCR tests and Antibody tests are available and have become part of the official testing strategy. Link 12. Link

**COVID: Travel Restrictions**

Restriction	Ends	Detail
Inbound travel	3 March 2021	<p>Entry restrictions:</p> <p>A) Inbound travel for European nationals: European nationals are able to enter Germany.</p> <p>B) Inbound travel for "third-country" nationals: Germany allows unrestricted entry for residents of Australia, New Zealand, Singapore, South Korea and Thailand.</p> <p>Third-country nationals are permitted to enter Germany if they are skilled and highly qualified foreign workers whose employment is necessary from an economic perspective and whose work cannot be postponed or performed abroad. The categories of permitted travellers can be reviewed at <a href="https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/which-skilled-and-highly-qualified-foreign-workers-are-permitted-to-enter-Germany.html">https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/which-skilled-and-highly-qualified-foreign-workers-are-permitted-to-enter-Germany.html</a></p> <p>Third-country nationals with residency are allowed to enter. This includes those with student visas.</p> <p>Additionally, some allowances are made for family matters: <a href="https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/travel-restriction-border-control-list.html#14104798">https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/travel-restriction-border-control-list.html#14104798</a></p> <p>C) Inbound travel for COVID-19 variant areas: Germany has imposed a general ban on travel and entry from countries with widespread occurrence of COVID-19 variants. At present, this includes Austria (only Tyrol state), Botswana, Brazil, Czech Republic, Eswatini, Ireland, Lesotho, Malawi, Mozambique, Portugal, South Africa, the UK, Zambia and Zimbabwe. This is in place until at least 3 March. This ban does not cover German citizens and residents or those transiting German airports.</p> <p>D) Border closures: All of Germany's borders remain open. Since Tyrol state (Austria) and the Czech Republic are rated as COVID-19 variant areas, border checks are in place for land movements to enforce the respective restrictions.</p>

**COVID: Travel Restrictions**

Restriction	Ends	Detail
Inbound travel	3 March 2021	<p>Entry restrictions:</p> <p>A) Inbound travel for European nationals: European nationals are able to enter Germany.</p> <p>B) Inbound travel for "third-country" nationals: Germany allows unrestricted entry for residents of Australia, New Zealand, Singapore, South Korea and Thailand.</p> <p>Third-country nationals are permitted to enter Germany if they are skilled and highly qualified foreign workers whose employment is necessary from an economic perspective and whose work cannot be postponed or performed abroad. The categories of permitted travellers can be reviewed at <a href="https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/which-skilled-and-highly-qualified-foreign-workers-are-permitted-to-enter-Germany.html">https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/which-skilled-and-highly-qualified-foreign-workers-are-permitted-to-enter-Germany.html</a></p> <p>Third-country nationals with residency are allowed to enter. This includes those with student visas.</p> <p>Additionally, some allowances are made for family matters: <a href="https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/travel-restriction-border-control-list.html#14104798">https://www.bmi.bund.de/SharedDocs/faq/EN/topics/civil-protection/coronavirus/travel-restrictions-border-control/travel-restriction-border-control-list.html#14104798</a></p> <p>C) Inbound travel for COVID-19 variant areas: Germany has imposed a general ban on travel and entry from countries with widespread occurrence of COVID-19 variants. At present, this includes Austria (only Tyrol state), Botswana, Brazil, Czech Republic, Eswatini, Ireland, Lesotho, Malawi, Mozambique, Portugal, South Africa, the UK, Zambia and Zimbabwe. This is in place until at least 3 March. This ban does not cover German citizens and residents or those transiting German airports.</p> <p>D) Border closures: All of Germany's borders remain open. Since Tyrol state (Austria) and the Czech Republic are rated as COVID-19 variant areas, border checks are in place for land movements to enforce the respective restrictions.</p>

**Airport Precautionary Measures**

Frankfurt: <https://www.frankfurt-airport.com/en/transfer-at-frankfurt-airport/covid-19/safety.html>

Düsseldorf: <https://www.dus.com/en/services/unbesorgt-starten>

Munich: <https://www.munich-airport.com/traveling-in-times-of-the-coronavirus-pandemic-8395611>

Dresden / Leipzig: <https://www.mdf-ag.com/presse/pressemitteilungen/details/reisehinweis>

Hamburg: [https://www.hamburg-airport.de/en/current\\_information.php#](https://www.hamburg-airport.de/en/current_information.php#)

Berlin: <https://www.berlin-airport.de/en/company/latest-news/news/2020/2020-06-10-fliegen-corona/index.php>

**Entry/Transit Requirements**

<https://www.auswaertiges-amt.de/en/einreiseundaufenthalt/coronavirus>


**Digital Entry Application (DEA)** - <https://www.einreiseanmeldung.de/>

<https://www.lufthansa.com/de/en/entry-into-germany/risk-level>


[https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Risikogebiete\\_neu.htm](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Risikogebiete_neu.htm)

**Entry from high risk areas**  
All travellers to Germany from a level 2 risk area must present a negative Corona/Covid-19 test upon departure. The proof of the negative Corona/Covid-19 test must not be older than 48 hours at the time of entry and is checked by the transport

**MAKE INFORMED DECISIONS**



# PROVIDE SUPPORT TO YOUR STAFF



# Vaccination referral & arrangements where available



SPIN is only compatible with Internet Explorer 11. Search results may vary when using another browser.

I am looking for:  Near:  Location or Country or City:  Within:  Select:  Who accepts:

Phase engage with the respective Lead Centre for referral request pertaining to this search.

Home > Search Results

4 Facilities found. Sort By: COVID Preference, Rank, Distance. View: [Map] [Satellite] [List]

**GP Plus Ltd (12737)**  
24 Dundas Street, Edinburgh, EH1 1LN, United Kingdom  
+44 (0)131 556489  
www.gpplus.com

**London Doctors Clinic Covent Garden (145033)**  
678 New Street, Covent Garden (WC2N 3SA), London, United Kingdom  
+44 20 2650 0547  
https://www.londondoctorclinic.co.uk

**Fleet Street Clinic (28285)**  
29 Fleet Street, London, EC4A 3DF, London, United Kingdom  
+44 (0)2079326678  
www.fleetstreetclinic.co.uk

**SPIN 7.0 N2**

My Tasks Reports Admin Billing Agency Employee View

Quick Search

Provider ID:  Name:  Country/City:  Speciality (Intuitive):  Rank:

Select Pricing:  Preferred Pricing Indicator:  near:  Enter a location

Provider Family:  Provider Category:  Provider Type:

Customer:  Program:  Care Area:

SOS Pandemic Management

COVID 19 PCR  
COVID 19 Rapid Diagnostic Test (Antigen)  
COVID 19 Rapid Diagnostic Test (Antibody)  
COVID 19 Vaccine (Johnson & Johnson)  
COVID 19 Vaccine (Pfizer-BioNTech)  
COVID 19 Vaccine (Moderna)  
COVID 19 Vaccine (Pfizer-BioNTech)  
COVID 19 Vaccine (Sandoz-GSK)  
COVID 19 Vaccine (Sinopharm)  
COVID 19 Vaccine (Sinovac)

SPIN 7.0 N2

+ Add Provider

Search All GAN Centers | Reset | Change Territory | Advanced Search

Rank:  FC + P + C

Search Less Options



SUPPORT & ASSIST  
EMPLOYEES







# COVID-19 VACCINATION SUPPORT SERVICES


## Plan and implement your vaccination strategy



Vaccine programmes supply & administration



Advisory on COVID-19 vaccination strategy & planning



# Vaccination strategy & planning

## Advisory services



Access to our global network of health consultants to support your vaccination planning, including:

- **Strategic advice** customised per location and employee profiles
- **Vaccination monitoring** and **national vaccine program information**
- **Vaccine education & training** programs
- **Vaccine delivery** strategies



**ASSESS RISKS  
& PLAN**

1.

### Monitoring

Vaccine status information on country readiness, analysis of info

2.

### Education

Getting over vaccine hesitancy

3.

### Preparation

Process & protocol review, GAP analysis

4.

### Sourcing

Support with implementation

Data last refreshed: 24/03/2021 18:02 UTC

IntlSOS Pandemic Status Limited Activity	Latest Data 23/03/2021	Vaccine Program Start 22/02/2021	Vaccines Available Ox/AZ, P/BN	Gov. Roll-out Policy 2G	Vaccine Pipeline				
Total Cases 29,221 Prev: 29,211 (-0.03%)	New Case 7DA 10 Prev: 11 (+9.46%)	Total Vaccinations 307,525 Prev: 282,184 (+8.98%)	Total Vaccinations /100 1.21 Prev: 1.11 (+0.10)	Mo to 70% Pop Vacc 66	Vaccine	Approval?	Doses Purchased	Doses needed for regimen	% Vaccine Coverage
Daily Vacs (7DA) 17,870 Prev: 16,772 (+1,098)					Oxford / AstraZenec...	Approved with conditions	53,800,000	2	105%
% Vacc /day (7DA) 0.07% Prev: 0.00 (+0.00%)					Pfizer/Biontech	Approved with conditions	20,000,000	2	39%
People Fully Vacc					COVAX Facility (GAVI)			2	
People Fully Vacc /100					CSL			2	
Vacc vs Case Grip Ratio					Novavax INUVX-Cov2		51 000 000	2	100%
					<b>Total</b>		<b>124,800,000</b>		<b>245%</b>

## Health Consulting Vaccine Advisory

## Overall advisory from Health Consultant

Phase 1B commenced 22 March, with the first of 1,000 GP practices starting to vaccinate. COVID-19 vaccine rollout update on 22 March 2021 <https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-on-22-march-2021>

The Therapeutic Goods Administration (TGA) has approved local manufacture of the AstraZeneca vaccine by CSL-Seqirus in Melbourne <https://www.tga.gov.au/media-release/tga-approves-csl-seqirus-manufacture-astrazeneca-covid-19-vaccine-australia>.

In relation to the suspension of the use of AstraZeneca vaccines by some countries, the Australian Technical Advisory Group on Immunisation (ATAGI) issued a statement <https://pandemic.internationalosos.com/reports/who-advises-vaccination-with-astrazeneca-should-continue-mar-13-2021> saying "Based on evidence to date, ATAGI do not see any reason to pause use of the AstraZeneca vaccine in Australia." They noted "the rates of thrombotic events are not higher in vaccine recipients than the expected background rate" but are monitoring the situation.

The vaccination program started on 22 February. Vaccination is provided free of charge.


Attribute	Value
Possibility for employers to actively offer Covid-19 vaccination to their employees as of now	Evolving
Non-national access to vaccines (comment)	Yes permanent residents and temporary visa-holders
International SOS recommendation on running vaccination communication	Not thought appropriate
International SOS recommendation on running vaccination programme	May become appropriate later
WHO assess countries need assistance to implement vaccination	No
Confidence of healthcare to	Very Confident

ASSESS RISKS  
& PLAN

## Vaccine Programme Summary

Attribute	Value
Date of vaccine programme start	2/22/2021
Comments	Vaccinations with Pfizer began 22 Feb, and AZ 5 March. Group 1b started 22 March with the first of 1,000 GP practices <a href="https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-on-22-march-2021">https://www.health.gov.au/resources/publications/covid-19-vaccine-rollout-update-on-22-march-2021</a>
Vaccination Programme (official references)	<a href="#">🔗</a>
Vaccination Programme (other references)	<a href="#">🔗</a>
Type of Rollout	
Vaccination Policy (URL)	<a href="#">🔗</a>
Communication links	
Detail of specific groups	
How do you get vaccine	Some GP Practices are contacting their eligible patients. People can check their eligibility at the website <a href="https://covid-vaccine.healthdirect.gov.au/eligibility">https://covid-vaccine.healthdirect.gov.au/eligibility</a> , which takes eligible people through to identifying clinic and making a booking  GP clinics can be found on this list <a href="https://www.health.gov.au/resources/publications/covid-19-vaccination-phase-1b-rollout">https://www.health.gov.au/resources/publications/covid-19-vaccination-phase-1b-rollout</a> , or through entering your postcode here <a href="https://covid-vaccine.healthdirect.gov.au/booking/?sid=b60c14c083636bec11fcb17cbbdfa5206ded7232">https://covid-vaccine.healthdirect.gov.au/booking/?sid=b60c14c083636bec11fcb17cbbdfa5206ded7232</a>
Vaccination Record	Australians can already access their immunisation history statement through Medicare for proof of vaccination, both digitally and in hard copy, if required. Statements can be viewed on an individual's Medicare online account or via the Medicare app. Your immunisation history statement will record your COVID-19 vaccinations, following each dose.  News 6 Feb: vaccination recorded in Australian Immunisation Register certificate is emailed
Other comments	5 March - presentation for requirements for 1B rollout Presentation - initial towns for phase 1 A rollout <a href="https://www.health.gov.au/resources/publications/priority-groups-for-covid-19-vaccination-program-phase-1b">https://www.health.gov.au/resources/publications/priority-groups-for-covid-19-vaccination-program-phase-1b</a>





# Vaccine programmes

## Supply & administration



As the situation progressively evolves, we remain in contact with vaccine manufacturers and national health authorities.

When access and distribution becomes available to the private corporate sector, we will be at the forefront in supporting you with **supplying and administering the vaccine for your employees.**



**ASSESS RISKS  
& PLAN**

**1.**  
**Transport, Storage, Dispersal**  
Cold chain facilities, security of storage, spoilage

**2.**  
**Screening**  
Eligibility vs. exclusion

**3.**  
**Delivery**  
Administration, observation, staffing & documentation

**4.**  
**Follow Up**  
Process for return in 2 weeks

**5.**  
**NPI Fatigue**  
Keep mask wearing, distancing, hand washing

**6.**  
**Travel**  
When & how to do this, help on the ground

**7.**  
**Vaccines Overseas**  
Where could you send your employees soon



# COVID-19 VACCINATION SUPPORT SERVICES

## A comprehensive programme from planning to daily execution







INTERNATIONAL  
SOS

**Thank you!**

For any questions please contact us at:  
**Switzerland@internationalsos.com**  
**Italy@internationalsos.com**

WORLDWIDE REACH. HUMAN TOUCH.